Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jerry Foltz

Interventional Pain Medicine Jacksonville, FL Medical Doctor

NPI 1144290677 CMS profile 1249550

4796 Hodges Blvd, Suite 101-104, Jacksonville, FL 32224

Open in the dashboard

General payments

$13,092

336 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jerry Foltz of Jacksonville, FL is reported in the CMS Open Payments database as having received $13,092 across 336 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,624 52
2024 General $1,205 29
2023 General $4,066 75
2022 General $1,429 44
2021 General $2,338 48
2020 General $1,108 47
2019 General $1,323 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerry Foltz
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Jerry Foltz were reported at $1,624. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Jerry Foltz Interventional Pain Medicine median Middle half National median
2019 $1,323 $684 $216–$2,079 $163
2020 $1,108 $382 $122–$1,109 $114
2021 $2,338 $552 $167–$1,554 $132
2022 $1,429 $605 $187–$1,924 $149
2023 $4,066 $671 $195–$1,915 $160
2024 $1,205 $684 $206–$1,837 $164
2025 $1,624 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $4,004 72 payments
  2. Genesys Orthopedics Systems, L.L.C. $1,103 7 payments
  3. Relievant Medsystems, Inc. $773 5 payments
  4. Nevro Corp. $710 13 payments
  5. Avanos Medical $541 7 payments
  6. AbbVie, Inc. $519 22 payments
  7. Medtronic, Inc. $506 10 payments
  8. Abbott Laboratories $378 17 payments
  9. Amgen Inc. $321 7 payments
  10. Lundbeck LLC $290 8 payments
  11. Other $3,948 168 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,404 322 payments
  2. Travel and Lodging $2,635 10 payments
  3. Gift $28 2 payments
  4. Education $25 2 payments
Products named General payments · program years 2019–2025
  1. SACROILIAC JOINT FUSION SYSTEM $1,103 7 payments
  2. Intracept Pain $877 6 payments
  3. Intracept Pain $773 5 payments
  4. Intracept Pain $773 5 payments
  5. Intracept Pain $773 5 payments
  6. WaveWriter Alpha Prime 16 $645 20 payments
  7. AIMOVIG $459 15 payments
  8. Senza Spinal Cord Stimulation System $427 8 payments
  9. GENERATOR $372 3 payments
  10. Superion Indirect Decompression System $366 6 payments
  11. Other $7,781 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

4,446

Median for Pain Management: 951

Drug cost

$157,589

Median for Pain Management: $26,034

Branded share of claims

58.5%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,093 $32,494
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,229 $25,106
Xtampza Er Oxycodone Myristate Brand 61 $24,036
Nucynta Tapentadol Hcl Brand 27 $22,471
Pregabalin Generic 469 $10,071
Oxycodone Hcl Generic 448 $9,038
Belbuca Buprenorphine Hcl Brand 12 $6,276
Ztlido Lidocaine Brand 14 $5,191
Buprenorphine Generic 26 $4,202
Morphine Sulfate Er Morphine Sulfate Brand 119 $3,138

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$569,323

Of which drugs: $20,402

Medicare patients

328

Average age 72

Services billed

12,452

185 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 39%
Diabetes 35%
Chronic kidney disease 34%
Depression 31%
Atrial fibrillation 23%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 13 16 $6,486
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 88 570 $413
Injection, ketorolac tromethamine, per 15 mg J1885 Office 13 68 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $33
$33 — —
QULIPTA
  • AbbVie, Inc. $28
$28 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $24
$24 12 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $18
$18 61 —
VYEPTI
  • Lundbeck LLC $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

336 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record